

Datasheet for ABIN1534731  
**anti-CBR1 antibody (AA 181-230)**



[Go to Product page](#)

2 Images

## Overview

Quantity:	100 µL
Target:	CBR1
Binding Specificity:	AA 181-230
Reactivity:	Human
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This CBR1 antibody is un-conjugated
Application:	Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

## Product Details

Immunogen:	The antiserum was produced against synthesized peptide derived from human CBR1.
Isotype:	IgG
Specificity:	CBR1 Antibody detects endogenous levels of total CBR1 protein.
Purification:	The antibody was purified from rabbit antiserum by affinity-chromatography using immunogen.
Purity:	> 95 %

## Target Details

Target:	CBR1
Alternative Name:	CBR1 ( <a href="#">CBR1 Products</a> )
Background:	Synonyms: Carbonyl reductase [NADPH] 1, NADPH-dependent carbonyl reductase 1,

## Target Details


	Prostaglandin-E(2) 9-reductase, Prostaglandin 9-ketoreductase, 15-hydroxyprostaglandin dehydrogenase [NADP+], CBR1, CBR, CRN NCBI Gene Symbol: CBR1
Molecular Weight:	30 kDa
Gene ID:	873
OMIM:	114830
UniProt:	<a href="#">P16152</a>

## Application Details

Application Notes:	WB: 1:500~1:1000 IHC: 1:50~1:100 ELISA: 1:40000
Comment:	Unigene-Number: Hs.606200, Hs.88778 (NCBI Gene Symbol: CBR1)
Restrictions:	For Research Use only


## Handling

Format:	Liquid
Concentration:	1 mg/mL
Buffer:	phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.
Preservative:	Sodium azide
Precaution of Use:	This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage:	-20 °C
Storage Comment:	Stable at -20°C for at least 1 year.
Expiry Date:	12 months



Western Blotting

**Image 1.** Western blot analysis of extracts from HeLa cells, using CBR1 Antibody. The lane on the right is treated with the synthesized peptide.



Immunohistochemistry

**Image 2.** Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue, using CBR1 Antibody. The picture on the right is treated with the synthesized peptide.